english.prescrire.org > Prescrire International > N°146 - February 2014

n°146

February 2014

Issue Contents
Editorial

Free  Generics: just who can be trusted?

p.32
False truths, misconceptions and unfounded beliefs

Marketing Authorisations

Apixaban and atrial fibrillation (New Indication)

p.33-36
No clear advantage

Glycopyrronium for inhalation (New Drug)

p.36-39
COPD: another antimuscarinic with cardiac adverse effects that require monitoring

Abiraterone and metastatic prostate cancer (New Indication)

p.40-41
Delays pain onset, cytotoxic therapy, and possibly death

Bacillus Calmette-Guerin and bladder cancer (New Drug)

p.41-42
Helpful packaging

INN common stem: -zomib

p.42

Adverse Effects

Atypical neuroleptics: compulsive disorders

p.43-44
Monitor patients for changes in behaviour

Nicardipine and preterm labour: pulmonary oedema

p.44
Cardiovascular risk for both mother and child

Free  Etoricoxib: a French review of adverse effects

p.45
Serious cardiovascular and gastrointestinal disorders

Free  Pregabalin: cardiac adverse effects

p.45
Rhythm and conduction disorders

Toxic epidermal necrolysis and related syndromes: a Spanish pharmacovigilance review

p.46
About 900 reports, providing useful information

"Grastims" and fatal capillary leak syndrome

p.46
Rare, serious adverse effect

Pregnant women are still exposed to acitretin

p.46
French data

Reviews

Recurrent uncomplicated cystitis in women

p.47-49
Allowing patients to self-initiate antibiotic therapy

Asthma in pregnancy

p.50-51
Drugs of choice and drugs to avoid

Drugs to avoid during pregnancy: omalizumab and montelukast, too many uncertainties

p.51

Outlook

Generics: keep a balanced view

p.52-55
Wise substitution ensures risk-free cost savings

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe